Tumor growth was monitored every 3 days, and we observed slower tumor progression in the shTP63 group compared to the ctrl group, suggesting that TP63 knockdown sensitized tumors to RSL3 treatment (Fig. 6I, J). The gene discussed is TP63; the disease is neoplasm.